Even as other drugmakers are making big plays for business in Japan, India’s Lupin is backing off. Just weeks after selling the sterile manufacturing assets of its Kyowa operation, it has now unloaded the rest of Kyowato a private equity investor.
Lupin today announced it will sell Kyowa Pharmaceutical Industry Co. to Japanese private equity fund Unison for ¥57.4 billion ($526 million) and expects to net about ¥32.6 billion ($300 million) on the deal. Lupin acquired the business in 2007 for about $60 million
The deal includes manufacturing facilities in Sanda and Tottori, Japan and a R&D center at Osaka, Lupin said.
“This transaction is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth in the mid to long-term,” Lupin CEO Vinita Gupta said in a statement. “The deal proceeds will be utilized to strengthen Lupin’s balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets.”
The operation makes a variety of generic products but Lupin said it is particularly strong in the “central nervous system/neurology space.” With about $260 million in sales in fiscal 2019, Lupin said the Kyowa operations ranks fifth in the Japanese generic market.
This deal comes three months after Lupin sold the sterile injectables plant and portfolio of Kyowa to Abu Dhabi-based Neopharma for an undisclosed sum. It also comes as Lupin has been dealing with FDA concerns over some of its manufacturing that will likely require investments. The FDA in September issued a warning letter for Lupin’s finished dose plant in Mandideep, India.
The Lupin Kyowa deal is actually part of a Japan M&A double feature. Novartis’ Sandoz unit announced it is buying the Japanese operations of South Africa’s Aspen Pharmacare for up to €400 million. In that case, Aspen will continue to manufacture drugs for Sandoz for up to seven years. That deal comes as Novartis has yet to complete a $1 billion sale of some plants and a portfolio of 300 drugs to India’s Aurobindo as it tries to remake its exposure in the difficult U.S. generics market.
By Eric Palmer
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
